Author

Kazi Mokim Ahmed

Baylor College of MedicineORCID 0000-0001-6575-5293Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Assay:metabolomics· 1

Frequent Co-Authors

Abdullah A. OsmaniD· 2 shared Faye M. JohnsoniD· 2 shared Jeffrey N. MyersiD· 2 shared Mitchell J. FrederickiD· 2 shared Pedram YadollahiiD· 2 shared Vlad Constantin SandulacheiD· 2 shared Adel K. El‐NaggariD· 1 shared Chandrashekar R. AmbatiiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Abdullah A. OsmanORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

NOTCH1 Acts as a Tumor Suppressor That Induces Early Differentiation in Head and Neck Cancer

Chenfei Huang, Shhyam Moorthy, Qiuli Li, Kazi Mokim Ahmed, Kalil Saab, Defeng Deng, Jiping Wang, Xiayu Rao, Jiexin Zhang, Yuanxin Xi, Jing Wang, Zhiyi Liu, Noriaki Tanaka, David A. Wheeler, Eve Shinbrot, , Mitchell J. Frederick

This study clarifies that NOTCH1 acts as a tumor suppressor in head and neck cancer, reducing cancer stem cells and improving prognosis, despite conflicting prior reports.

JCI Insight · Apr 16, 2026Peer-reviewedCancer Biology

Bypassing cisplatin resistance in Nrf2 hyperactivated head and neck cancer through effective PI3Kinase targeting

Pedram Yadollahi, Kelli A. McCord, Li Yang, Hussam Dayoub, Kalil Saab, Fonma Essien, Sean Hyslop, Emerald Kan, Kazi Mokim Ahmed, Parker R. Kirby, Vasanta Putluri, Chandrashekar R. Ambati, Karthik Reddy Kami Reddy, Patricia D. Castro, Heath Devin Skinner, , Vlad Constantin Sandulache

This paper identifies PI3K pathway activation in Nrf2-driven cisplatin-resistant HNSCC and shows that gedatolisib inhibits tumor growth and re-sensitizes cells to cisplatin.

British Journal of Cancer · Oct 6, 2025Peer-reviewedCancer Biology